You are now leaving a Radius Health controlled website. Radius Health does not endorse and is not responsible for the accuracy, content, practices, procedures or standards of any non-Radius Health websites.
Repositioned the Company to create meaningful P+L operating leverage Dramatic improvement in Adj. EBITDA performance: ($6) million in Q2, 2021 vs. ($29) million in Q2, 2020 FY 2021 guidance: reiterate Adj. EBITDA of $10 million while reducing TYMLOS revenue from $250 to $240 million TYMLOS Q2, 2021
Added 5,000+ new TYMLOS patients in Q2, 2021, up 40+% vs. Q2, 2020 and 3% vs. Q1, 2021 ATOM and wearABLe abaloparatide Phase 3 trial readouts remain on track for 2H, 2021 EU abaloparatide regulatory resubmission remains on schedule for Q4, 2021 Prader-Willi Syndrome (PWS) pivotal Phase 2/3 study to
FDA Type C meeting minutes provide clarity on the Phase 2/3 study design for RAD011 505(b)(2) regulatory strategy: acceptable approach upon completion of PK & food effect studies Based on results, a single well controlled study could serve as the basis for marketing approval RAD011 had previously
BOSTON , July 20, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Thursday, August 5, 2021 . The Company will host a conference call and live audio webcast at 8:30 a.m.
TYMLOS ® new patient adds in April: modest growth vs. previous 4-month trailing averages ~67% of new patients in April were initiated by a fracture focused bone health account Meaningful FDA guidance on generic peptide requirements published on May 19, 2021 Anticipate abaloparatide depot
Total net revenue: $56 million vs. $48 million in Q1, 2020, +17% year-over-year TYMLOS ® U.S. product net revenue: $45 million vs. $48 million in Q1, 2020, -6% year-over-year Significant operating leverage improvement: Q1, 2021 adjusted EBITDA: ($5) million vs.
Growth of 14% for new U.S. TYMLOS® patients in Q1, 2021 vs. Q4, 2020 Q1, 2021 TYMLOS net revenue impacted by seasonality and distribution channel destocking April, 2021 month-to-date new patient adds indicate significant patient growth Three pivotal studies: all remain on track for 2H, 2021
BOSTON , April 20, 2021 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter financial results on Friday, May 7, 2021 . The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a
Regulatory success achieved in Japan by partner Teijin Pharma Limited Ostabaro® approved for treatment of male & female OP patients at high risk of fracture Japan is currently the largest anabolic market in the world $10 million milestone to be generated from Japan approval EU: intend to re-file
Repurchases $112.2 million of principal amount of the 3.00% convertible notes due September 1, 2024 (“2024 Notes”), representing approximately 37% of the outstanding 2024 Notes Estimated excess cash proceeds of approximately $14.2 million will be added to the balance sheet Eliminates approximately